Last reviewed · How we verify
TEZSPIRE (TEZEPELUMAB-EKKO)
TEZSPIRE (generic name: TEZEPELUMAB-EKKO) is a Thymic Stromal Lymphopoietin Blocker [EPC] drug developed by ASTRAZENECA AB. It is currently FDA-approved for Severe asthma.
Tezepelumab is being studied in a post-marketing study in Japan for its long-term effects in patients with bronchial asthma. The study, TEZSPIRE Subcutaneous Injection 210mg Specific Use-results Study (Long Term), is comparing the effects of tezepelumab to a placebo in patients with severe or intractable bronchial asthma.
At a glance
| Generic name | TEZEPELUMAB-EKKO |
|---|---|
| Sponsor | ASTRAZENECA AB |
| Drug class | Thymic Stromal Lymphopoietin Blocker [EPC] |
| Target | Thymic stromal lymphopoietin |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
Approved indications
- Severe asthma
Common side effects
- Pharyngitis
- Arthralgia
- Back pain
- Injection site reactions
Serious adverse events
- Serious cardiac adverse events
- Major adverse cardiovascular events (MACE)
Key clinical trials
- A Multicentre, Single-Arm, Phase 3b Study to Assess Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab (ESSENCE) (Phase 3)
- A Randomized, Double-blinded, Parallel, Positive-controlled Study to Compare the Pharmacokinetic, Safety and Immunogenicity of Single-dose QL2302 vs. Tezspire ® in Healthy Subjects (Phase 1)
- Tezepelumab in the Treatment of Co-morbid Allergic Rhinitis and Allergic Asthma Study (TEZARS) - An Open-Label Exploratory Mechanistic Pilot Study to Evaluate Tezepelumab Efficacy in Asthma and Allerg (Phase 2)
- A Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 157 in Healthy Subjects and Subjects With (Phase 1)
- A Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 157 in Healthy Subjects (Phase 1)
- Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea (N/A)
- Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 157 in Subjects With Mild Atopic A (Phase 1)
- TEZSPIRE Subcutaneous Injection 210mg Specific Use-results Study (Long Term) in Patients With Bronchial Asthma. (N/A)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TEZSPIRE CI brief — competitive landscape report
- TEZSPIRE updates RSS · CI watch RSS
- ASTRAZENECA AB portfolio CI
Frequently asked questions about TEZSPIRE
What is TEZSPIRE?
What is TEZSPIRE used for?
Who makes TEZSPIRE?
What is the generic name of TEZSPIRE?
What drug class is TEZSPIRE in?
What development phase is TEZSPIRE in?
What are the side effects of TEZSPIRE?
What does TEZSPIRE target?
Related
- Drug class: All Thymic Stromal Lymphopoietin Blocker [EPC] drugs
- Target: All drugs targeting Thymic stromal lymphopoietin
- Manufacturer: ASTRAZENECA AB — full pipeline
- Therapeutic area: All drugs in Respiratory
- Indication: Drugs for Severe asthma
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing